AbbVie Inc. $ABBV Shares Bought by Washburn Capital Management Inc.

Washburn Capital Management Inc. lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 36.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,610 shares of the company’s stock after purchasing an additional 1,771 shares during the period. AbbVie accounts for about 0.8% of Washburn Capital Management Inc.’s holdings, making the stock its 23rd biggest position. Washburn Capital Management Inc.’s holdings in AbbVie were worth $1,729,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. James T. Borello RIA increased its stake in AbbVie by 3.5% in the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company’s stock valued at $312,000 after buying an additional 40 shares during the last quarter. ACT Advisors LLC. boosted its stake in shares of AbbVie by 2.5% in the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after buying an additional 41 shares during the last quarter. Willner & Heller LLC boosted its stake in shares of AbbVie by 0.7% in the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after buying an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC boosted its stake in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after buying an additional 43 shares during the last quarter. Finally, Fielder Capital Group LLC grew its holdings in shares of AbbVie by 1.7% in the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after acquiring an additional 43 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $282.95 on Tuesday. The firm has a market cap of $499.91 billion, a price-to-earnings ratio of 79.93, a P/E/G ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $291.40. The firm’s 50-day simple moving average is $263.44 and its two-hundred day simple moving average is $239.87.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the firm earned $2.97 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie’s dividend payout ratio is presently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s investigational ABBV-466, which targets both IL-23 p19 and integrin α4β7, produced higher endoscopic remission rates in moderate-to-severe Crohn’s disease than either monotherapy at Week 12. The treatment advantage widened by Week 24, while biomarker analyses indicated intestinal tissue repair and barrier restoration. The results improve the drug’s potential as a differentiated next-generation immunology product. AbbVie ABBV-466 Crohn’s disease data
• Positive Sentiment: Analysts viewed the Crohn’s findings favorably because ABBV-466 outperformed AbbVie’s established blockbuster Skyrizi in a mid-stage comparison, highlighting the company’s strategy of combining complementary immune mechanisms. The data could help extend AbbVie’s leadership in inflammatory diseases if confirmed in later-stage trials. AbbVie Crohn’s combination beats Skyrizi
• Positive Sentiment: AbbVie announced its largest-ever presence at the 2026 ESMO Congress, with data from seven oncology assets spanning lung, colorectal, ovarian, prostate and gastric cancers. Updates on antibody-drug conjugates, precision medicines, Elahere and other programs could provide additional pipeline catalysts when presented October 23–27. AbbVie 2026 ESMO oncology data
• Neutral Sentiment: Investors are also watching AbbVie’s neuroscience franchise ahead of quarterly results. Analysts anticipate roughly 16% third-quarter revenue growth from established therapies and newer Parkinson’s treatments, but the outlook will depend on the company’s upcoming earnings report. AbbVie neuroscience franchise outlook

Analysts Set New Price Targets

A number of analysts recently commented on ABBV shares. Cantor Fitzgerald increased their price target on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. BNP Paribas Exane boosted their price objective on AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Leerink Partners boosted their price objective on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Piper Sandler upped their price objective on AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Finally, Weiss Ratings raised AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.